76263-11-1

Usage

Uses

Since the provided materials do not specify any particular uses for ETHYL 2-AMINO-4,5,6,7-TETRAHYDRO-1,3-BENZOTHIAZOLE-4-CARBOXYLATE, it is not possible to list its applications based on the given information. Further research and study would be required to determine its potential uses in various industries.

InChI:InChI=1/C10H14N2O2S/c1-2-14-9(13)6-4-3-5-7-8(6)12-10(11)15-7/h6H,2-5H2,1H3,(H2,11,12)

Upstream product

• 1655-07-8 ethyl 2-oxocyclohexane carboxylate 
• 30132-23-1 ethyl 3-bromo-2-oxocyclohexanecarboxylate 
• 17356-08-0 thiourea 

Downstream Products

• 405071-51-4 toluene-4-sulfonic acid 2-amino-4,5,6,7-tetrahydro-benzothiazol-4-ylmethyl ester 
• 1190391-84-4 2-((tert-butoxycarbonyl)amino)-4,5,6,7-tetrahydrobenzo[d]thiazole-4-carboxylic acid 
• 1558057-84-3 C₃₆H₄₆N₄O₆S 
• 1558057-83-2 C₃₆H₄₆N₄O₆S 
• 1190389-26-4 C₂₆H₃₀N₄O₂S 
• 1190389-25-3 (R)-2-amino-N-(4-(((2S,5R)-5-((R)-hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4,5,6,7-tetrahydrobenzo[d]thiazole-4-carboxamide 
• 1369897-34-6 ethyl 2-((tert-butoxycarbonyl)amino)-4,5,6,7-tetrahydrobenzo[d]thiazole-4-carboxylate 
• 729590-69-6 2-bromo-4,5,6,7-tetrahydro-benzothiazole-4-carboxylic acid ethyl ester 
• 882490-35-9 (S)-4-((di-o-tolylphosphino)methyl)-2-phenyl-4,5,6,7-tetrahydrobenzo[d]thiazole 
• 882490-26-8 (S)-4-((diphenylphosphino)methyl)-2-phenyl-4,5,6,7-tetrahydrobenzo[d]thiazole 
• 882490-20-2 (S)-(2-phenyl-4,5,6,7-tetrahydrobenzo[d]thiazol-4-yl)methyl 4-methylbenzenesulfonate 
• 882490-37-1 (S)-4-((di-o-tolylphosphino)methyl)-4,5,6,7-tetrahydrobenzo[d]thiazole 
• 882490-36-0 (S)-4-((diphenylphosphino)methyl)-4,5,6,7-tetrahydrobenzo[d]thiazole 
• 882490-31-5 (S)-(4,5,6,7-tetrahydrobenzo[d]thiazol-4-yl)methyl 4-methylbenzenesulfonate 

Relevant academic research and scientific papers

Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective β3 adrenergic receptor agonists for the treatment of overactive bladder

A series of conformationally restricted acetanilides were synthesized and evaluated as β3-adrenergic receptor agonists (β3-AR) for the treatment of overactive bladder (OAB). Optimization studies identified a five-membered ring as the preferred conformational lock of the acetanilide. Further optimization of both the aromatic and thiazole regions led to compounds such as 19 and 29, which have a good balance of potency and selectivity. These compounds have significantly reduced intrinsic clearance compared to our initial series of pyridylethanolamine β3-AR agonists and thus have improved unbound drug exposures. Both analogues demonstrated dose dependent β3-AR mediated responses in a rat bladder hyperactivity model.

MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

COMBINATION THERAPY USING A BETA 3 ADRENERGIC RECEPTOR AGONIST AND AN ANTIMUSCARINIC AGENT

Described herein is an improved method of treating overactive bladder, wherein the method comprises administering to a patient in need thereof a beta 3 adrenergic receptor agonist, an antimuscarinic agent, and an optional selective M2 antagonist. Such combination therapy provides improved efficacy and/or reduced side effects.

HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS

The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS

The present invention is directed to compounds represented by the following structural formula, Formula I: wherein (a) X is selected from the group consisting of a single bond, O, S. S(O)2 and N; (b) U is an aliphatic linker; (c) Y is selected from the group consisting of C, O, S, NH and a single bond; (d) E is C(R3) (R4)A or A and wherein (i) A is selected from the group consisting of carboxyl, tetrazole, C1-C6 alkylnitrile, carboxamidek, sulfonamide and acylsulfonamide; (e) B is selected from the group consisting of S, O, C, and N; (f) Z is selected from the group consisting of N and C; with the proviso that when B is C then Z is N.

A convenient synthesis of 4-aminomethyl-4,5,6,7-tetrahydro-1,3-benzothiazole arginine side-chain mimetics

A convenient synthesis of novel 4-aminomethyl-4,5,6,7-tetrahydro-1,3-benzothiazole arginine side-chain mimetics designed for incorporation into thrombin inhibitors is reported.

Condensed Tetrahydrobenzothiazoles: Part I- Synthesis of 2-Substituted Anilino-4,5,6,7-tetrahydrobenzothiazoles and Their 4-Carbethoxy Derivatives

Condensation of the appropriate 2-halocyclohexanone (I) with arylthiourea (II) affords a number of 2-substituted anilino-4,5,6,7-tetrahydrobenzothiazoles (IIIa) and their 4-carbethoxy esters (IIIb).Influence of steric factors and nucleophilicity of the reactants on the course of this reaction are discussed.